TORONTO, ON - TheNewswire - May 13, 2025 - StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), and ElevationMD ( “ElevationMD”) today announced the introduction of Aristotle and AVRT for the early detection of cancer as well as screening for metabolic markers for identifying and managing the early warning signs of chronic disease for the prevention of cancer. StageZero is an integrated... Read More

StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its third quarter financial results for... Read More

StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its second quarter financial results for... Read More

TORONTO, ON / ACCESSWIRE / July 3, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive metabolic treatment protocol with early data - METRICS study - showing an... Read More

TORONTO, ON / ACCESSWIRE / May 23, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in... Read More

TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced... Read More

TORONTO, ON / ACCESSWIRE / April 5, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in... Read More

TORONTO, ON / ACCESSWIRE / April 2, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in... Read More

TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, today... Read More

Aristotle and AVRT to be offered to My One Medical Source's Customer Base TORONTO, ON / ACCESSWIRE / November 14, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment... Read More

Care Oncology Partners with WellnessScript to Offer Mental Health support to cancer patients TORONTO, ON / ACCESSWIRE / November 7, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical... Read More

CareOncology partners with The Source Functional Nutrition to offer nutritional guidance to cancer patients. TORONTO, ON / ACCESSWIRE / October 20, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and... Read More

Toronto, Ontario--(Newsfile Corp. - June 20, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that it has applied to the Toronto Stock Exchange (the " Exchange... Read More

Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - StageZero Life Sciences, Ltd (TSX: SZLS) (OTCQB: SZLSF) ("StageZero" or the "Company") is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company's management information circular dated April 28 2023 (the "Circular"), at its annual and special meeting of shareholders held on June 07, 2023(the "Meeting"). The results of the... Read More

Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) ("StageZero" or the "Company") today announced that it will host a conference call as part of its Special and Annual General Meeting of Shareholders on Wednesday June 7, 2023, so that all shareholders may follow along with the proceedings of the meeting. Annual General and Special Meeting Conference Call Event Date : Wednesday June... Read More

Toronto, Ontario--(Newsfile Corp. - May 16, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company"), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its first quarter financial results for the three months ended March 31, 2023, and... Read More

Toronto, Ontario--(Newsfile Corp. - May 15, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its first quarter 2023 operational results after the market closes on Monday May 15, 2023. StageZero's Chairman and CEO, James Howard-Tripp, will host an investor webcast and conference call at 8:30am ET on Tuesday May 16, 2023, reviewing the operational results and... Read More

Toronto, Ontario--(Newsfile Corp. - March 31, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company"), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its fourth quarter and full year financial results for the three and twelve-months... Read More

Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its fourth quarter and year end 2022 operational results after the market closes on Friday March 31, 2023. StageZero's Chairman and CEO, James Howard-Tripp, will release a webcast presentation at 7:00am ET on Monday April 3, 2023, reviewing the operational results and... Read More

Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - StageZero Life Sciences (TSX: SZLS) ("StageZero" or the "Company") today announced that it will release its fourth quarter and year end 2022 operational results after the market closes on Thursday March 30, 2023. StageZero's Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 6:00 p.m. ET on Thursday March 30, 2023, to review the... Read More

Launch of New Protocol will now make the connection between patients' metabolic health and cancer outcomes using advanced biomarker testing and interactive digital health platform to actively track patient progress. Toronto, Ontario--(Newsfile Corp. - February 15, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) (" StageZero " or the " Company "), a global healthcare company providing solutions to help... Read More

Toronto, Ontario--(Newsfile Corp. - February 2, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced today that its special meeting (the "Meeting") originally... Read More

TORONTO, ON / ACCESSWIRE / January 12, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that it has applied to the Toronto Stock Exchange (the " Exchange ") to... Read More

TORONTO, ON / ACCESSWIRE / November 21, 2022 / StageZero Life Sciences Ltd. ("StageZero" or the "Company") (TSX:SZLS) today announced that it has entered into a capital commitment agreement (the "Agreement") with GEM Global Yield LLC SCS ("GGY") for a CAD $25 million Capital Commitment ("CC"). Draw downs are at the Company's discretion and subject to the terms as described in detail in the Financing Terms below. Proceeds... Read More

StageZero Life Sciences, Ltd (TSX:SZLS) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, is pleased to announce that it closed a private placement of units (each a " Unit ") for gross proceeds of $177,000 on August 18, 2022 (the "... Read More

Personalized support for employees through all stages of the patient journey includes advanced diagnostics, interventional support, and innovative telehealth care StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics... Read More

StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) (OTCQB:SZLSF), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its second quarter financial results for the three months ended June 30, 2022, and provided an update on its business... Read More

StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) today announced that it will release its second quarter operational and financial results before the markets open on Tuesday, August 16, 2022. StageZero's Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 8:30 a.m. EDT on Tuesday August 16, 2022, to review the operational results and discuss business developments to... Read More

StageZero Life Sciences, Ltd (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company") is pleased to report that shareholders voted in favour of all of the tabled resolutions listed in the Company's management information circular dated May 12, 2022 (the "Circular"), at its annual and special meeting of shareholders held on June 28, 2022 (the "Meeting"). The results of the vote for the election of directors are as follows: For... Read More

StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced that Matthew Pietras has resigned as CFO and COO. Mr. Pietras will support the Company during the transition to a new... Read More

First-ever mRNA gene expression, multi-cancer panel simultaneously screens for multiple cancers from a single sample of blood StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today... Read More

StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS)(OTCQB:SZLSF), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its first quarter financial results for the three months ended March 31, 2022, and provided an update on its business... Read More

StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced the worldwide launch of the COC Plus Program for patients currently in the COC Protocol / TREAT Program. COC Plus... Read More

StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) today announced that it will release its first quarter financial results before the market open on Tuesday May 17, 2022. StageZero's Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 8:30 a.m. EDT on Tuesday May 17, 2022, to review the operational results and discuss business developments. Analyst and Investor Call... Read More

StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced a corporate update and addressed the recently share price activity. In light of recent pricing pressure, the Company wants to reiterate... Read More

StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its fourth quarter and full year financial results for the three and twelve-months ended December 31, 2021, and provided an update on its... Read More

Innovative program helps identify and address the early warning signs of cancer and chronic disease StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced the launch of... Read More

StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS) today announced that it will release its fourth quarter and year end 2021 operational results before the market open on Friday April 1, 2022. StageZero's Chairman and CEO, James Howard-Tripp, will host a conference call and accompanying webcast at 8:30 a.m. EST on Friday April 1, 2022, to review the operational results and discuss business developments.... Read More

StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the... Read More

StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, is pleased to announce that it has closed its previously announced private placement of its common shares (" Common Shares ") and warrants to... Read More

StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) (" StageZero " or the " Company "), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that it has applied to the Toronto Stock Exchange (the " Exchange ") to extend the expiry date of 5,702,314.00... Read More

Noted industry experts Dr. Barry Boyd, Dr. Jason Fung, and Benjamin Bikman, Ph.D. join StageZero Life Sciences' Scientific Advisory Board to advance the Company's mission of improving cancer and other chronic disease outcomes through early detection and intervention StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early... Read More

Teams up with OK2Roam and VFS Global to streamline COVID-19 testing protocols for travelers from Canada and the U.S. StageZero Life Sciences , Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced... Read More

StageZero Life Sciences , Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced that it has engaged Richmond Hill based SRCO Professional Corporation ("SRCO") as its auditors. McGovern Hurley LLP... Read More

StageZero Life Sciences , Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, is pleased to report that shareholders today approved at a special meeting the issuance of 8,000,000 common shares of the Company to... Read More

Convenient, reliable COVID-19 PCR saliva test kits available at Sobeys Inc. pharmacies across Canada StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its BORDERPASS™ COVID-19 RT-PCR... Read More

First-ever mRNA multi-cancer panel simultaneously screens for multiple cancers from a single sample of blood StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced that... Read More

Easy-to-use COVID-19 PCR saliva test allows U.S. and Canadian travelers to self-collect samples from their home, office, or hotel room StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions,... Read More

StageZero Life Sciences (TSX:SZLS) ("StageZero" or the "Company"), a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, today announced its third-quarter financial results for the three months ended September 30, 2021, and provided an update on its business progress. The... Read More

Activities will include a national educational awareness campaign, health economics research, and clinical studies aimed at earlier detection of testicular, brain, and colorectal cancers StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through... Read More

StageZero Life Sciences (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading edge molecular diagnostics and clinical interventions, today announced a corporate update. As previously announced, Richard Huston has now been appointed to the StageZero Life Sciences Board of... Read More

StageZero Life Sciences (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through lab developed tests and clinical interventions, today announced that it will release its third-quarter 2021 operational results after the market closes on Monday November 15, 2021. Management will host a live conference call... Read More